ADGI NASDAQ
Waltham, MA 02451
US
Adagio Therapeutics, Inc. is a clinical-stage biopharmaceutical firm, primarily focused on the discovery, development, and subsequent commercialization of antibody-based therapeutics designed to combat infectious diseases across the United States. Its most advanced product candidate, ADG20 (adintrevimab), is a neutralizing antibody currently undergoing Phase 3 clinical trials. This antibody is being evaluated for both the treatment and prevention of coronavirus disease. Adagio Therapeutics also engages in strategic collaborations. It partners with Adimab, LLC to facilitate the discovery and optimization of novel proprietary antibodies. Furthermore, the company works with the Scripps Research Institute on research initiatives aimed at identifying vaccine candidates that could prevent, diagnose, or treat influenza and beta coronaviruses. Founded in 2020, Adagio Therapeutics maintains its headquarters in Waltham, Massachusetts.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Hering David | P-Purchase | 8,000 | $4.52 | 2022-09-01 |
| M28 Capital Manageme | P-Purchase | 584,451 | $4.62 | 2022-08-17 |
| Hering David | A-Award | 2,000,000 | — | 2022-07-05 |
| MEANWELL CLIVE | A-Award | 150,000 | — | 2022-06-22 |
| Berry Tamsin | A-Award | 150,000 | — | 2022-06-22 |